From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness.
Cervical cancer
Eradication
Human papillomavirus
Vaccination
Journal
Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
05
09
2020
revised:
29
11
2020
accepted:
04
12
2020
pubmed:
15
12
2020
medline:
29
6
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
The Director-General of the World Health Organization has called for global action towards elimination of cervical cancer as a public health problem. Cervical cancer is caused by human papillomavirus (HPV), an infectious agent with no non-human reservoir. One way to achieve this is through very high levels of vaccine coverage that could enable global eradication of vaccine-type HPV. Using the case study of India, we show that HPV eradication can meet all the Dahlem and Strüngmann criteria for feasibility of eradication. It can be achieved with 90% gender-neutral HPV vaccine coverage together with 95% coverage in high-risk groups such as female sex workers. Such a strategy would likely be cost-effective compared to no vaccination. Although it would be more costly in the short-term than achieving cervical cancer elimination alone, it would save costs in the long-term by removing or at least sharply reducing the need for preventive measures.
Identifiants
pubmed: 33309871
pii: S0091-7435(20)30385-6
doi: 10.1016/j.ypmed.2020.106354
pmc: PMC7957342
pii:
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106354Subventions
Organisme : Department of Health
ID : NIHR200929
Pays : United Kingdom
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
J Infect Dis. 2017 Aug 1;216(3):336-344
pubmed: 28859431
Philos Trans R Soc Lond B Biol Sci. 2013 Jun 24;368(1623):20120149
pubmed: 23798697
Lancet Public Health. 2016 Nov;1(1):e8-e17
pubmed: 29253379
J Infect Dis. 1996 Oct;174 Suppl 2:S201-13
pubmed: 8843250
Lancet Glob Health. 2020 Apr;8(4):e536-e544
pubmed: 32105613
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
J Clin Virol. 2016 Mar;76 Suppl 1:S56-S61
pubmed: 26525202
Int J Cancer. 2016 Dec 15;139(12):2771-2780
pubmed: 27541596
Bull World Health Organ. 2007 Jan;85(1):2
pubmed: 17242748
Int J Gynaecol Obstet. 2016 Mar;132(3):259-65
pubmed: 26851054
Vaccine. 2015 Aug 26;33(36):4520-4525
pubmed: 26192351
Lancet Oncol. 2015 May;16(5):e217-25
pubmed: 25943066
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301
Vaccine. 2012 Nov 20;30 Suppl 5:F123-38
pubmed: 23199956
Philos Trans R Soc Lond B Biol Sci. 2013 Jun 24;368(1623):20120137
pubmed: 23798686
Lancet. 2020 Feb 22;395(10224):575-590
pubmed: 32007141
Lancet. 2020 Feb 22;395(10224):591-603
pubmed: 32007142
Lancet Glob Health. 2014 Jul;2(7):e406-14
pubmed: 25103394
Vet Comp Oncol. 2003 Mar;1(1):3-14
pubmed: 19379325
PLoS One. 2014 Jun 26;9(6):e101114
pubmed: 24968002
J Natl Cancer Inst. 2016 Oct 18;109(2):
pubmed: 27754955
PLoS One. 2017 Jun 2;12(6):e0177773
pubmed: 28575074